NovaBridge Biosciences is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Rockville, MD. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $632 thousand and a loss of $88 million (its filed statements).
Pre-revenue companyPharmaceutical PreparationsRockville, MDfilings since 20196 of 9 filed, 3 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.4 out of ten, 6 of 9 metrics filed and 3 estimated: past 4.6 out of ten, present 2.6 out of ten, future 5.9 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2019. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 2.0 out of ten. -73.9% a year over 4 filed years; profitable in 1 of 4. 20th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 5.8 out of ten. CrossAssetData estimate 5.8/10, confidence 35 of 100 (one part). 59th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 480 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Industry position (present): 0.9 out of ten. bottom 9% of 314 in its family; net margin -5302%. 9th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 0.3 out of ten. CrossAssetData estimate 0.3/10, confidence 35 of 100 (one part). 3rd percentile among 414 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Room to expand (future): 8.6 out of ten. top 14% of 272 in its family for room to expand. 86th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.6 out of ten. top 44% of 307 in its family for growth drivers. 56th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 2.4 out of ten. bottom 24% of 234 in its family for expectations against reality. 24th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-04-07 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 4, 2026-09-21. Filings on record since 2019. Read from EDGAR 2026-10-12.
Who runs it
Gupta, Srishti (Chief Executive Officer); Fu, Xi-Yong (Chief Executive Officer and Director Exhibit List: Ex. 24.1 - Power of Attorney); Wu, Joanna Xuqiong (Senior Vice President, Head of Operations, General Counsel (US) Exhibit List: Ex. 24.1 - Power of Attorney); Lei, Ming Kyler (Chief Financial Officer); Dennis, Phillip Andrew (Chief Medical Officer); Cao, Sean Wuxiong (Chief Bus. Development Officer); Hagler, Mark Arnold (Chief Commercial Officer); Zhang, Xiaofan Neo (Chief Investment Officer); Xu, Cong Claire (EVP, Clinical Development); Lin, Liwei Lorraine (General Counsel); and 10 more. 20 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.